Marijuana-Based Parkinson’s Medication Moves Forward
CannaMD
APRIL 23, 2020
In a 2005 paper , Dr. Bob Melamede noted that endocannabinoid dysregulation might be a causal factor in the disease’s development, detailing how the Parkinson’s disease-related glutamatergic problems of lab rodents could be “suppressed by exo- as well as endocannabinoids.” To learn more about GB Sciences, see: GBSciences.com.
Let's personalize your content